Literature DB >> 18084252

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.

Lluis Catasus1, Alberto Gallardo, Miriam Cuatrecasas, Jaime Prat.   

Abstract

Mutations of the oncogene PIK3CA occur frequently in endometrial carcinomas, but their prognostic significance is unclear. To determine the clinicopathological and molecular implications of these mutations, PIK3CA status was investigated in 109 endometrial (102 endometrioid and 7 mixed) carcinomas and the results were compared with clinicopathological parameters associated with prognosis. Tumors were also investigated for microsatellite instability and PTEN, beta-catenin gene (CTNNB1), K-RAS, and B-RAF mutations. We found 35 PIK3CA somatic missense mutations in 32 (29%) endometrial carcinomas. Eighteen mutations occurred in exon 20 (kinase domain), and 17 in exon 9 (helical domain). Almost all mutated tumors were pure endometrioid adenocarcinomas. All tumors with PIK3CA mutations exhibited myometrial invasion (P=0.032). Lymphovascular invasion was found more frequently in mutated (28%) than nonmutated carcinomas (18%). Histological grade varied significantly according to the location of the PIK3CA mutations whether in exon 9 or exon 20 (P=0.033). The frequency of exon 9 mutations was higher in grade 1 carcinomas (57%) than in grade 2 (29%) or grade 3 (14%) tumors. Conversely, mutations in exon 20 were more common in grade 3 (60%) than in grade 2 (20%) or grade 1 (20%) carcinomas. None of the tumors confined to the endometrium (stage IA) had PIK3CA mutations. Furthermore, whereas 64% of adenocarcinomas with exon 9 mutations had invaded < or =(1/2) of the myometrial thickness (stage IB), 73% of tumors with exon 20 mutations had either deeper myometrial invasion (stage IC) or cervical involvement (stage II) (P=0.045). PIK3CA mutations coexisted with microsatellite instability and mutations in PTEN, CTNNB1, K-RAS, and B-RAF genes. These results favor that PIK3CA mutations are associated with myometrial invasion and, moreover, that tumors harboring PIK3CA mutations in exon 20 are frequently high-grade, deeply invasive endometrial carcinomas that tend to exhibit lymphovascular invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084252     DOI: 10.1038/modpathol.3800992

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  32 in total

1.  Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors:  Li-E Wang; Hongxia Ma; Katherine S Hale; Ming Yin; Larissa A Meyer; Hongliang Liu; Jie Li; Karen H Lu; Bryan T Hennessy; Xuesong Li; Margaret R Spitz; Qingyi Wei; Gordon B Mills
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-07       Impact factor: 4.553

Review 2.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 3.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

4.  PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.

Authors:  Shannon N Westin; Zhenlin Ju; Russell R Broaddus; Camilla Krakstad; Jane Li; Navdeep Pal; Karen H Lu; Robert L Coleman; Bryan T Hennessy; Samuel J Klempner; Henrica M J Werner; Helga B Salvesen; Lewis C Cantley; Gordon B Mills; Andrea P Myers
Journal:  Mol Oncol       Date:  2015-05-16       Impact factor: 6.603

5.  Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.

Authors:  Eman Abdulfatah; Sharif Sakr; Sumi Thomas; Zaid Al-Wahab; David G Mutch; Sean Dowdy; Sudeshna Bandyopadhyay; Adnan Munkarah; Mohamed Elshaikh; Robert Morris; Rouba Ali-Fehmi
Journal:  Int J Gynecol Cancer       Date:  2017-10       Impact factor: 3.437

6.  Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.

Authors:  Yingmei Wang; Da Yang; David Cogdell; Limei Hu; Fengxia Xue; Russell Broaddus; Wei Zhang
Journal:  Technol Cancer Res Treat       Date:  2010-04

7.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

8.  Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

Authors:  Huan Pang; Rory Flinn; Antonia Patsialou; Jeffrey Wyckoff; Evanthia T Roussos; Haiyan Wu; Maria Pozzuto; Sumanta Goswami; John S Condeelis; Anne R Bresnick; Jeffrey E Segall; Jonathan M Backer
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

Review 9.  Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Authors:  Sandra B Gabelli; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Biochim Biophys Acta       Date:  2009-12-02

10.  Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Authors:  Kimberly K Leslie; Michael W Sill; Heather A Lankes; Edgar G Fischer; Andrew K Godwin; Heidi Gray; Russell J Schilder; Joan L Walker; Krishnansu Tewari; Parviz Hanjani; Ovadia Abulafia; Peter G Rose
Journal:  Gynecol Oncol       Date:  2012-08-07       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.